LU91703I2 - Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) - Google Patents

Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)

Info

Publication number: LU91703I2
Authority: LU; Luxembourg
Prior art keywords: galactosidase; mammalian cell; acid residues; biologically active; sialic acid
Prior art date: 1992-11-30

Application number

LU91703C

Other languages

English (en)

Original Assignee

Sinai School Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-30

Filing date

2010-06-24

Publication date

2010-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25529958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91703(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-24 Application filed by Sinai School Medicine filed Critical Sinai School Medicine

2010-08-24 Publication of LU91703I2 publication Critical patent/LU91703I2/fr

Links

108010056760 agalsidase beta Proteins 0.000 title 2
229960004470 agalsidase beta Drugs 0.000 title 1
KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 1
229940014516 fabrazyme Drugs 0.000 title 1
210000004962 mammalian cell Anatomy 0.000 abstract 4
210000004027 cell Anatomy 0.000 abstract 2
238000004113 cell culture Methods 0.000 abstract 2
238000012258 culturing Methods 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000009450 sialylation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Virology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU91703C 1992-11-30 2010-06-24 Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) LU91703I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/983,451 US5401650A (en)	1990-10-24	1992-11-30	Cloning and expression of biologically active α-galactosidase A
EP94902448A EP0670896B2 (fr)	1992-11-30	1993-11-30	Clonage et expression d'alpha-galactosidase a biologiquement active
EP00200454A EP1020528A3 (fr)	1992-11-30	1993-11-30	Méthode de production de protéines secrétées

Publications (1)

Publication Number	Publication Date
LU91703I2 true LU91703I2 (fr)	2010-08-24

Family

ID=25529958

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91704C LU91704I2 (fr)	1992-11-30	2010-06-24	Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)
LU91703C LU91703I2 (fr)	1992-11-30	2010-06-24	Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU91704C LU91704I2 (fr)	1992-11-30	2010-06-24	Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)

Country Status (14)

Country	Link
US (2)	US5401650A (fr)
EP (4)	EP2210947B1 (fr)
JP (2)	JP4005629B2 (fr)
AT (2)	ATE464386T1 (fr)
AU (1)	AU691795B2 (fr)
CA (1)	CA2150555C (fr)
DE (3)	DE122010000028I1 (fr)
DK (3)	DK0670896T3 (fr)
ES (3)	ES2168101T5 (fr)
IL (4)	IL220131A0 (fr)
LU (2)	LU91704I2 (fr)
PT (3)	PT1942189E (fr)
SE (1)	SE2210947T5 (fr)
WO (1)	WO1994012628A1 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040064855A1 (en) *	1988-02-26	2004-04-01	Large Scale Biology Corporation	Production of lysosomal enzymes in plants by transient expression
US6846968B1 (en)	1988-02-26	2005-01-25	Large Scale Biology Corporation	Production of lysosomal enzymes in plants by transient expression
US5179023A (en) *	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
AU688310B2 (en) *	1993-03-26	1998-03-12	New York Blood Center, Inc., The	Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en)	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
NZ506214A (en) *	1996-09-13	2002-11-26	Transkaryotic Therapies Inc	Therapy for alpha-galactosidase A deficiency
AU2012227349B2 (en) *	1996-09-13	2015-12-24	Shire Human Genetic Therapies, Inc.	Therapy for alpha-galactosidase A deficiency
IL155588A0 (en) *	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US6455037B1 (en) *	1996-11-01	2002-09-24	Mount Sinai School Of Medicine Of The City University Of New York	Cells expressing an αgala nucleic acid and methods of xenotransplantation
US6210666B1 (en)	1997-10-21	2001-04-03	Orphan Medical, Inc.	Truncated α-galactosidase A to treat fabry disease
EP1027069B1 (fr) *	1997-10-29	2006-07-26	Genzyme Corporation	Thérapie génique pour la maladie de gaucher
EP1658857A1 (fr) *	1997-10-29	2006-05-24	Genzyme Corporation	Compositions et méthodes pour le traitement de maladies lysosomales
CA2354846A1 (fr) *	1998-12-23	2000-06-29	Regeneron Pharmaceuticals, Inc.	Technique permettant d'accroitre l'activite biologique de ligands
AU2016250357B2 (en) *	1999-03-11	2018-11-01	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) *	1999-03-11	2016-07-28	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
US6534300B1 (en) *	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en)	1999-09-14	2004-08-03	Genzyme Glycobiology Research Institute, Inc.	Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
CN1312383A (zh) *	2000-03-07	2001-09-12	上海博德基因开发有限公司	一种新的多肽——人alpha－半乳糖苷酶A－11和编码这种多肽的多核苷酸
US7138262B1 (en)	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
US7629309B2 (en) *	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
EP1436316B1 (fr) *	2001-04-30	2008-01-23	ZyStor Therapeutics , Inc.	Ciblage intracellulaire de proteines therapeutiques
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
JP4742191B2 (ja) *	2001-06-14	2011-08-10	独立行政法人産業技術総合研究所	糖蛋白質およびその製造方法
US7767415B2 (en)	2001-09-25	2010-08-03	Velico Medical, Inc.	Compositions and methods for modifying blood cell carbohydrates
EP2292273A3 (fr)	2001-10-10	2011-11-23	BioGeneriX AG	Remodelage et Glycoconjugaison de Peptides
US20030072761A1 (en) *	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US6905856B2 (en)	2001-12-21	2005-06-14	Genzyme Glycobiology Research Institute, Inc.	Soluble GlcNAc phosphotransferase
US20030124652A1 (en) *	2001-12-21	2003-07-03	Novazyme Pharmaceuticals, Inc.	Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) *	2001-12-21	2004-10-05	Genzyme Glycobiology Research Institute, Inc.	Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US7658916B2 (en) *	2002-04-05	2010-02-09	Genzyme Corporation	Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
DK1503788T3 (da) *	2002-04-25	2011-10-17	Shire Human Genetic Therapies	Behandling af alpha-galactosidase A-deficiens
JP5589165B2 (ja)	2003-01-31	2014-09-17	マウントシナイスクールオブメディシンオブニューヨークユニバーシティー	タンパク質欠損性障害の治療のための併用療法
CA2522345A1 (fr)	2003-04-09	2004-11-18	Neose Technologies, Inc.	Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US7951557B2 (en)	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
US20050137223A1 (en) *	2003-11-12	2005-06-23	Amicus Therapeutics, Inc.	Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
DE602005020745D1 (de) *	2004-02-10	2010-06-02	Zystor Therapeutics Inc	Saure alpha-glukosidase und fragmente davon
WO2006007560A2 (fr)	2004-07-01	2006-01-19	University Of Pennsylvania	Remplacement de proteines ciblees pour le traitement de maladies lysosomales
CN101389273B (zh) *	2004-08-05	2012-09-05	贝勒研究院	基因或药物递送系统
EP3782655A1 (fr)	2005-05-17	2021-02-24	Amicus Therapeutics, Inc.	Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés
US8470318B2 (en)	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP4368925B2 (ja) *	2005-11-18	2009-11-18	財団法人東京都医学研究機構	基質特異性を変換した新規高機能酵素
ES2391657T3 (es)	2006-02-07	2012-11-28	Shire Human Genetic Therapies, Inc.	Composiciones estabilizadas de proteínas que tienen un resto tiol libre
GB0606190D0 (en)	2006-03-28	2006-05-10	Isis Innovation	Construct
AU2007235413B2 (en)	2006-04-05	2012-08-02	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007322123A1 (en) *	2006-11-13	2008-05-29	Biomarin Pharmaceutical Inc.	Methods for treating Pompe disease
ES2660667T3 (es)	2007-05-07	2018-03-23	Protalix Ltd.	Biorreactor desechable a gran escala
US8742079B2 (en) *	2007-08-20	2014-06-03	Protalix Ltd.	Saccharide-containing protein conjugates and uses thereof
WO2009102895A2 (fr) *	2008-02-12	2009-08-20	Amicus Therapeutics, Inc.	Méthode de prédiction de la réponse de certaines maladies a un traitement pharmacologique à base de chaperon moléculaire
JP2011517960A (ja)	2008-04-22	2011-06-23	ザロックフェラーユニバーシティー	抗炎症化合物の識別方法
WO2009137721A2 (fr)	2008-05-07	2009-11-12	Zystor Therapeutics, Inc.	Peptides de ciblage lysosomial et leurs utilisations
US8592555B2 (en) *	2008-08-11	2013-11-26	Emd Millipore Corporation	Immunoglobulin-binding proteins with improved specificity
MX2011003381A (es) *	2008-09-30	2011-04-21	Abbott Lab	Metodo mejorado para despliegue de arn.
SG195555A1 (en)	2008-12-24	2013-12-30	Emd Millipore Corp	Caustic stable chromatography ligands
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
US8785168B2 (en)	2009-06-17	2014-07-22	Biomarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
AU2010281403B2 (en)	2009-07-28	2016-03-10	Takeda Pharmaceutical Company Limited	Compositions and methods for treating Gaucher disease
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
WO2011108451A1 (fr) *	2010-03-01	2011-09-09	日本ケミカルリサーチ株式会社	Procédé de production d'enzymes lysosomales recombinantes au moyen de cellules présentant une inactivation de gène
DK2865751T3 (en)	2010-03-02	2017-01-09	Protalix Ltd	Stabilized alpha-galactosidase and uses thereof
US20130017169A1 (en)	2010-03-02	2013-01-17	Protalix Ltd.	Multimeric forms of therapeutic proteins and uses thereof
WO2012012461A2 (fr)	2010-07-19	2012-01-26	Shire Human Genetic Therapies, Inc.	Lignée cellulaire optimisée pour le codon de récepteur de mannose de type c 1 (mrc1) et ses utilisations
US8679478B2 (en)	2010-10-04	2014-03-25	Duke University	Methods of lysosomal storage disease therapy
CN103391784A (zh)	2010-10-15	2013-11-13	纽约市哥伦比亚大学理事会	肥胖症-相关的基因和它们的蛋白和其用途
PT2635299T (pt)	2010-11-02	2019-10-14	Univ Columbia	Métodos de tratamento de distúrbios de perda de cabelo
EP2665814B1 (fr)	2011-01-20	2017-05-17	Protalix Ltd.	Construction d'acide nucléique pour l'expression d'une alpha-galactosidase chez des plantes et des cellules végétales
SG10201604559TA (en)	2011-06-08	2016-07-28	Emd Millipore Corp	Chromatography matrices including novel staphylococcus aureus protein a based ligands
US10350277B2 (en)	2011-09-07	2019-07-16	Icahn School Of Medicine At Mount Sinai	Ceramidase and cell differentiation
WO2013130963A1 (fr)	2012-03-02	2013-09-06	Shire Human Genetic Therapies, Inc.	Composition et méthode de traitement de la maladie de gaucher de type iii
KR20200032244A (ko)	2012-03-07	2020-03-25	아미쿠스 세라퓨틱스, 인코포레이티드	폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US10039777B2 (en)	2012-03-20	2018-08-07	Neuro-Lm Sas	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da)	2012-03-29	2019-01-02	Univ Columbia	Fremgangsmåder til behandlng af hårtabsforstyrrelser
ES2786128T3 (es)	2012-06-01	2020-10-08	Icahn School Med Mount Sinai	Niveles de ceramida en el tratamiento y prevención de infecciones
WO2014016873A1 (fr)	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Procédé de production d'alpha-galactosidase a humaine recombinante
JP6832158B2 (ja)	2013-03-14	2021-02-24	アイカーンスクールオブメディシンアットマウントサイナイ	治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP2976092B1 (fr) *	2013-03-15	2020-04-22	Amicus Therapeutics, Inc.	Agents de réticulation chimiques
ES2891728T3 (es) *	2013-09-16	2022-01-31	Genzyme Corp	Métodos y sistemas para procesar un cultivo celular
TWI793159B (zh) *	2013-10-23	2023-02-21	美商健臻公司	重組醣蛋白及其用途
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
JP6851964B2 (ja)	2014-09-30	2021-03-31	アミカスセラピューティックスインコーポレイテッド	炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
WO2016116966A1 (fr) *	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
US9981021B1 (en)	2015-04-09	2018-05-29	Kinetiq, Inc.	Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
EP3347486A4 (fr)	2015-09-09	2019-06-19	The Trustees of Columbia University in the City of New York	Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
US10940125B2 (en)	2015-09-18	2021-03-09	Duke University	Methods and compositions for the treatment of steatosis-associated disorders
IL299470B2 (en)	2015-12-30	2026-05-01	Amicus Therapeutics Inc	Improved acid alpha-glucosidase for the treatment of Pompe disease
KR102618519B1 (ko)	2016-03-30	2023-12-28	아미쿠스 세라퓨틱스, 인코포레이티드	재조합 산 알파-글루코시다제를 포함하는 제형
CA3019354A1 (fr)	2016-03-30	2017-10-05	Amicus Therapeutics, Inc.	Procede de selection de proteines recombinees a teneur elevee en m6p
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (fr)	2016-10-14	2018-04-19	The Trustees Of Columbia University In The City Of New York	Procédés de traitement d'un trouble d'abus d'alcool
CN119113091A (zh)	2017-05-15	2024-12-13	阿米库斯治疗学公司	重组人类酸性α-葡萄糖苷酶
RU2698460C1 (ru) *	2019-03-28	2019-08-27	Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"	Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae
EP3996696A1 (fr)	2019-07-09	2022-05-18	Genethon	Traitement de la glycogénose (gsd)
CN112795583A (zh) *	2020-11-16	2021-05-14	上海大学	重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
WO2022100748A1 (fr) *	2020-11-16	2022-05-19	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Virus adéno-associés recombinés à tropisme hépatique amélioré et leurs utilisations
IL307770A (en) *	2021-04-20	2023-12-01	Walking Fish Therapeutics Inc	Engineering B-cells based on protein production for the treatment of serious diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH585793A5 (fr) *	1974-02-01	1977-03-15	Nestle Sa
JPS5322158B2 (fr) *	1974-05-02	1978-07-06
IT1130242B (it) *	1980-02-01	1986-06-11	Anic Spa	Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4925796A (en) *	1986-03-07	1990-05-15	Massachusetts Institute Of Technology	Method for enhancing glycoprotein stability
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
US5032519A (en) *	1989-10-24	1991-07-16	The Regents Of The Univ. Of California	Method for producing secretable glycosyltransferases and other Golgi processing enzymes
DE4028800A1 (de) *	1990-09-11	1992-03-12	Behringwerke Ag	Gentechnische sialylierung von glykoproteinen
US5382524A (en) *	1990-10-24	1995-01-17	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-n-acetylgalactosaminidase

1992
- 1992-11-30 US US07/983,451 patent/US5401650A/en not_active Expired - Lifetime
1993
- 1993-11-30 CA CA2150555A patent/CA2150555C/fr not_active Expired - Lifetime
- 1993-11-30 DE DE122010000028C patent/DE122010000028I1/de active Pending
- 1993-11-30 AT AT07022356T patent/ATE464386T1/de active
- 1993-11-30 EP EP10157183.4A patent/EP2210947B1/fr not_active Expired - Lifetime
- 1993-11-30 EP EP00200454A patent/EP1020528A3/fr not_active Ceased
- 1993-11-30 PT PT07022356T patent/PT1942189E/pt unknown
- 1993-11-30 JP JP51342394A patent/JP4005629B2/ja not_active Expired - Lifetime
- 1993-11-30 PT PT101571834T patent/PT2210947E/pt unknown
- 1993-11-30 IL IL220131A patent/IL220131A0/en unknown
- 1993-11-30 ES ES94902448T patent/ES2168101T5/es not_active Expired - Lifetime
- 1993-11-30 DK DK94902448T patent/DK0670896T3/da active
- 1993-11-30 DK DK07022356.5T patent/DK1942189T3/da active
- 1993-11-30 DE DE69331550T patent/DE69331550T3/de not_active Expired - Lifetime
- 1993-11-30 IL IL107814A patent/IL107814A/en active Protection Beyond IP Right Term
- 1993-11-30 EP EP94902448A patent/EP0670896B2/fr not_active Expired - Lifetime
- 1993-11-30 AT AT94902448T patent/ATE213020T1/de not_active IP Right Cessation
- 1993-11-30 WO PCT/US1993/011539 patent/WO1994012628A1/fr not_active Ceased
- 1993-11-30 ES ES10157183T patent/ES2431293T3/es not_active Expired - Lifetime
- 1993-11-30 PT PT94902448T patent/PT670896E/pt unknown
- 1993-11-30 DK DK10157183.4T patent/DK2210947T3/da active
- 1993-11-30 DE DE69334327T patent/DE69334327D1/de not_active Expired - Lifetime
- 1993-11-30 SE SE10157183T patent/SE2210947T5/xx unknown
- 1993-11-30 IL IL220132A patent/IL220132A0/en unknown
- 1993-11-30 IL IL200005A patent/IL200005A/en not_active IP Right Cessation
- 1993-11-30 AU AU56817/94A patent/AU691795B2/en not_active Expired
- 1993-11-30 ES ES07022356T patent/ES2344431T3/es not_active Expired - Lifetime
- 1993-11-30 EP EP07022356A patent/EP1942189B1/fr not_active Expired - Lifetime
1994
- 1994-06-17 US US08/261,577 patent/US5580757A/en not_active Expired - Lifetime
2003
- 2003-12-01 JP JP2003401467A patent/JP3598302B2/ja not_active Expired - Lifetime
2010
- 2010-06-24 LU LU91704C patent/LU91704I2/fr unknown
- 2010-06-24 LU LU91703C patent/LU91703I2/fr unknown

Also Published As

Publication number	Publication date
CA2150555A1 (fr)	1994-06-09
DK2210947T3 (da)	2013-10-07
IL220131A0 (en)	2012-07-31
LU91704I2 (fr)	2010-08-24
DE122010000028I1 (de)	2010-08-12
ATE213020T1 (de)	2002-02-15
US5580757A (en)	1996-12-03
IL200005A (en)	2013-09-30
US5401650A (en)	1995-03-28
ES2344431T3 (es)	2010-08-26
SE2210947T5 (fr)	2015-02-03
PT1942189E (pt)	2010-05-28
JPH08503615A (ja)	1996-04-23
EP2210947A3 (fr)	2010-10-06
IL220132A0 (en)	2012-07-31
DE69331550T3 (de)	2006-06-29
IL107814A0 (en)	1994-02-27
EP1942189B1 (fr)	2010-04-14
EP0670896A4 (fr)	1997-08-20
DK1942189T3 (da)	2010-06-07
JP3598302B2 (ja)	2004-12-08
EP0670896A1 (fr)	1995-09-13
CA2150555C (fr)	2010-11-02
EP2210947B1 (fr)	2013-07-17
EP1942189A2 (fr)	2008-07-09
WO1994012628A1 (fr)	1994-06-09
EP2210947A2 (fr)	2010-07-28
ES2168101T3 (es)	2002-06-01
IL107814A (en)	2012-12-31
DK0670896T3 (da)	2002-05-27
EP1020528A2 (fr)	2000-07-19
ATE464386T1 (de)	2010-04-15
ES2168101T5 (es)	2005-10-16
EP1942189A3 (fr)	2008-09-10
JP4005629B2 (ja)	2007-11-07
DE69331550D1 (de)	2002-03-21
EP1020528A3 (fr)	2000-10-04
ES2431293T3 (es)	2013-11-25
AU5681794A (en)	1994-06-22
PT670896E (pt)	2002-07-31
PT2210947E (pt)	2013-10-23
EP0670896B2 (fr)	2005-04-27
AU691795B2 (en)	1998-05-28
JP2004121260A (ja)	2004-04-22
DE69334327D1 (de)	2010-05-27
EP0670896B1 (fr)	2002-02-06
DE69331550T2 (de)	2002-09-26

Publication	Publication Date	Title
LU91704I2 (fr)	2010-08-24	Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)
DE60029091D1 (de)	2006-08-10	Verfahren zur herstellung von diphtheria toxin
FR2726003B1 (fr)	2002-10-18	Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
CA2237890A1 (fr)	1997-05-22	Induction in vitro de la chrondrogenese des cellules souches mesenchymateuses humaines
DK0733712T3 (da)	2002-03-18	Fremgangsmåde til fremstilling af et stof
ES8606489A1 (es)	1986-04-01	Un metodo de producir una proteina de interleuquina-2-humana no glicosilada sustancialmente pura
ES8202362A1 (es)	1982-01-01	Procedimiento para preparar un acido desoxi-ribonucleico (adn) recombinante
NO934776L (no)	1994-02-17	Rensing av rekombinant apoliproteiner E fra bakterier
ES2188708T3 (es)	2003-07-01	Metodo de produccion de acido l-lactico con alta pureza optica utilizando cepas de bacillus.
IL164523A0 (en)	2005-12-18	Cytokine receptor
KR910006483A (ko)	1991-04-29	재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
EP0837931A4 (fr)	1999-06-02	Procede d'expression et d'isolation de molecules biologiquement actives dans l'urine
EP1060241B2 (fr)	2010-10-20	Preparation de cellules pour la production de substances biologiques
SG3292G (en)	1992-03-20	Production of a-21978c derivatives
EP0321940A3 (en)	1990-05-23	An improved method for the preparation of natural human growth hormone in pure form
DE59611099D1 (de)	2004-11-04	Verfahren zur Nutzung des Hefe-ADH-II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
ATE145670T1 (de)	1996-12-15	Verfahren zur fermentativen herstellung von 2- hydroxyphenylessigsäure
DE3868712D1 (de)	1992-04-09	Ein neues antibiotikum, fumifungin, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel.
JPS5668395A (en)	1981-06-09	Production of d(-)-beta-hydroxyisobutyric acid
DE69429757D1 (de)	2002-03-14	Verfahren zur Herstellung einer Substanz
JPS6467193A (en)	1989-03-13	Production of 4-hydroxy-2,2,6-trimethylcyclohexanone
HK1030628B (en)	2007-04-27	Preparation of cells for production of biologicals
UA10461A (uk)	1996-12-25	Іhдуктор іhтерфероhу в клітиhах ссавців, які культивуються